<DOC>
	<DOC>NCT01127555</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.</brief_summary>
	<brief_title>Salvage mFOLFOX in BTC After Failure of Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. Age : older than 18 2. Histologically confirmed adenocarcinoma of the biliary tract 3. Metastatic or unresectable biliary cancer 4. Prior exposure to gemcitabine chemotherapy for biliary cancer 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 2 6. A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in spiral Computed Tomography (CT) or multidetector CT 7. Adequate bone marrow, liver, renal function 1. Pregnancy and breastfeeding. 2. Other serious illness or medical condition, notably heart or lung failure, active uncontrolled infection (infection requiring antibiotics). 3. Past or concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated insitu carcinoma of the cervix. 4. Symptomatic or uncontrolled brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Biliary Tract Cancer</keyword>
	<keyword>Salvage therapy</keyword>
	<keyword>FOLFOX</keyword>
</DOC>